Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atogepant and Ubrogepant DDI Study
NCT04818515Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of atogepant in migraine, sponsored by AbbVie Inc. Primary endpoints: Area Under the Plasma Concentration-time Curve from Time 0 to t, when Ubrogepant is Administered at Day 1, Area Under the Plasma Concentration-time Curve from Time 0 to t, when Ubrogepant and Atogepant are Coadministered at Day 1 and 8 more. Started Mar 2021; status: completed.
02
Drugs
atogepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04818515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04818515.